Merit Medical Systems Acquires View Point Medical for About $140 Million

Isoray Completes Merger with Viewpoint Molecular Targeting

February 6, 2023

Biotechnology

Isoray, Inc. completed an all-stock merger with Viewpoint Molecular Targeting, effective February 3, 2023, combining Isoray's brachytherapy expertise with Viewpoint's radiopharmaceutical and diagnostic pipeline. Under the deal each Viewpoint share converted into 3.1642 shares of Isoray (totaling 136,545,075 shares, ~49% of Isoray's outstanding shares); Viewpoint CEO Thijs Spoor was named CEO of the combined company and outgoing Isoray CEO Lori Woods became Chair.

HealthMark Group Acquires Purview

February 12, 2026

Healthcare Services

HealthMark Group acquired Purview, a cloud-based medical imaging company based in Annapolis, Maryland. The acquisition is intended to modernize how medical imaging is ingested, analyzed, and shared—moving away from widespread reliance on physical discs—by integrating Purview into HealthMark’s clinical data exchange solution.

Eli Lilly Acquires POINT Biopharma Global

December 27, 2023

Biotechnology

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

Merit Medical Acquires EsophyX Z+ Assets from EndoGastric Solutions

July 1, 2024

Medical Devices

Merit Medical Systems has executed an asset purchase agreement to acquire the EsophyX Z+ device and related assets from EndoGastric Solutions, Inc. for approximately $105 million in cash. The acquisition expands Merit’s gastrointestinal product portfolio and provides clinicians a minimally invasive treatment option for GERD via the EsophyX TIF 2.0 procedure.

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Healthcare Services

Bristol Myers Squibb will acquire Turning Point Therapeutics in a $4.1 billion, all-cash transaction at $76.00 per share under a definitive merger agreement. The deal was originally expected to close in Q3 2022, and the acquisition was completed in August 2022.

SD Biosensor and SJL Partners Acquire Meridian Bioscience for $1.53B

July 7, 2022

Medical Devices

A consortium led by SD Biosensor and private equity firm SJL Partners agreed to acquire Meridian Bioscience in an all-cash transaction valued at approximately $1.53 billion ( $34.00 per share). The deal will take Meridian private and is intended to accelerate SD Biosensor's entry into the U.S. in-vitro diagnostics market while leveraging Meridian's U.S. distribution network and product portfolio.